Dose Effect of Antithymocyte Globulin or Post-transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation: A Comparative Study
Open Access
- 26 April 2025
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (8) , 544.e1-544.e5
Abstract
No abstract availableKeywords
Funding Information
- Sanofi K.K.
This publication has 5 references indexed in Scilit:
- Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantationBritish Journal of Haematology, 2023
- Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemiaHaematologica, 2020
- Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte GlobulinCell Transplantation, 2020
- HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin)Hematology, 2016
- Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplantHaematologica, 2016